Valneva SE
PAR:VLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valneva SE
Long-Term Debt
Valneva SE
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€186.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€3.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€51.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Long-Term Debt
$101.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
100%
|
|
|
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$5.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Long-Term Debt
€52.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
90%
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Long-Term Debt?
Long-Term Debt
186.6m
EUR
Based on the financial report for Dec 31, 2025, Valneva SE's Long-Term Debt amounts to 186.6m EUR.
What is Valneva SE's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
9%
Over the last year, the Long-Term Debt growth was -3%. The average annual Long-Term Debt growth rates for Valneva SE have been 17% over the past three years , 14% over the past five years , and 9% over the past ten years .
